UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Purchases 22,896 Shares of Encompass Health Corporation $EHC

Key Points

• UBS AM increased its position in Encompass Health Corporation to $39.55 million by acquiring an additional 22,896 shares, bringing its total holdings to approximately 390,494 shares.
• Encompass Health reported a quarterly earnings per share (EPS) of $1.40, surpassing analysts' expectations of $1.20, and announced a dividend increase to $0.19 per share.
• Institutional investors now hold 97.25% of Encompass Health's stock, indicating strong institutional support for the company.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 6.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 390,494 shares of the company's stock after buying an additional 22,896 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.39% of Encompass Health worth $39,549,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also modified their holdings of the company. Dean Capital Management increased its stake in Encompass Health by 2.2% during the 1st quarter. Dean Capital Management now owns 22,680 shares of the company's stock worth $2,297,000 after buying an additional 483 shares in the last quarter. United Services Automobile Association acquired a new stake in shares of Encompass Health in the first quarter valued at $666,000. Aristeia Capital L.L.C. purchased a new position in Encompass Health in the first quarter valued at $277,000. Caxton Associates LLP purchased a new position in shares of Encompass Health during the first quarter worth about $259,000. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Encompass Health by 25.1% during the first quarter. Goldman Sachs Group Inc. now owns 1,119,259 shares of the company's stock worth $113,359,000 after buying an additional 224,477 shares during the period. Institutional investors and hedge funds own 97.25% of the company's stock.

Encompass Health Stock Performance

Shares of EHC stock traded down $1.39 on Friday, hitting $123.94. The company's stock had a trading volume of 1,428,682 shares, compared to its average volume of 602,788. The company has a market capitalization of $12.48 billion, a PE ratio of 24.25, a PEG ratio of 2.19 and a beta of 0.92. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.06 and a current ratio of 1.06. Encompass Health Corporation has a fifty-two week low of $87.85 and a fifty-two week high of $127.15. The stock's 50 day moving average is $118.12 and its 200-day moving average is $113.61.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.20 by $0.20. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The firm's quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter last year, the business earned $1.11 EPS. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. Equities research analysts expect that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.

Encompass Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Wednesday, October 1st will be paid a dividend of $0.19 per share. This is a boost from Encompass Health's previous quarterly dividend of $0.17. The ex-dividend date is Wednesday, October 1st. This represents a $0.76 annualized dividend and a yield of 0.6%. Encompass Health's dividend payout ratio (DPR) is 13.31%.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on EHC. UBS Group lifted their price target on shares of Encompass Health from $130.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, August 6th. Bank of America boosted their target price on shares of Encompass Health from $145.00 to $160.00 and gave the stock a "buy" rating in a research report on Wednesday, September 10th. Truist Financial boosted their price objective on shares of Encompass Health from $135.00 to $140.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. KeyCorp upped their target price on shares of Encompass Health from $135.00 to $140.00 and gave the stock an "overweight" rating in a research report on Tuesday. Finally, Wall Street Zen lowered shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. One analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company. According to data from MarketBeat, Encompass Health currently has an average rating of "Buy" and an average target price of $138.43.

Insiders Place Their Bets

In other news, EVP Patrick William Tuer sold 1,020 shares of Encompass Health stock in a transaction on Wednesday, August 27th. The stock was sold at an average price of $123.59, for a total transaction of $126,061.80. Following the sale, the executive vice president directly owned 18,846 shares in the company, valued at $2,329,177.14. The trade was a 5.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.00% of the company's stock.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.